Eli Lilly and Company has partnered with Nvidia to develop a powerful supercomputer aimed at accelerating drug discovery using artificial intelligence. This collaboration, announced in October and expanded in January with a $1 billion, five-year commitment, involves scientists and engineers from both companies working in a new Bay Area lab. The initiative seeks to leverage AI tools to discover new medicines, with other companies also pursuing similar AI-driven drug discovery efforts. AI
IMPACT Accelerates AI-driven drug discovery, potentially leading to faster development of new medicines.
RANK_REASON Significant collaboration between a major pharmaceutical company and a leading chip manufacturer to build AI infrastructure for drug discovery. [lever_c_demoted from significant: ic=1 ai=0.7]
Read on Mastodon — fosstodon.org →
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
